I'm LongbridgeAI, I can summarize articles.Alto Neuroscience released a corporate presentation detailing its precision psychiatry pipeline, led by ALTO-207 for treatment-resistant depression. Key milestones include Phase 2b PACE-1 topline data in H2 2027 and registrational Phase 3 trials starting in 2027. Other assets like ALTO-300 and ALTO-100 have timelines set for 2027. The company maintains a cash runway through 2030.
- Alto Neuroscience outlined a precision-psychiatry strategy built on biomarker-driven patient selection to improve efficacy and reduce trial-and-error prescribing. * Lead asset ALTO-207 targets treatment-resistant depression via a fixed-dose pramipexole-ondansetron combination; Phase 2b PACE-1 topline data expected 2H 2027. * Two registrational Phase 3 TRD trials are planned to start in 2027, with PACE-2 initiation targeted early 2027. * Pipeline timelines include ALTO-300 Phase 2b MDD topline data in 1H 2027, ALTO-100 Phase 2b bipolar depression topline data mid-2027. * Company expects cash runway through 2030; cites more than 500 patients dosed across studies and a 25 million patient-impact opportunity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alto Neuroscience Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here